Clinical trials have shown that palbociclib, in combination with hormonal therapies, can significantly prolong progression-free survival compared to hormonal therapy alone. This makes it a valuable option for patients with advanced breast cancer, offering them more time without disease progression and potentially improving their quality of life.
